- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06414161
Management of Radiotherapy-related Xerostomia With Green Tea and Peppermint
Management of Radiotherapy-related Xerostomia With Green Tea and Peppermint Oral Rinse: a Double-blind, Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Global Cancer Observatory from the World Health Organization estimates that head and neck cancer (HNC) incidence will reach approximately 1.5 million cases worldwide in 2020. Nevertheless, radiotherapy (RT) remains one of the cornerstone standard therapies to attenuate HNC progression. The advancement of linear accelerator (LINAC) technologies together with intensity-modulated radiation therapy (IMRT) techniques have enhanced the precision and efficiency of fractionated RT for HNC. Emerging research efforts have also been undertaken to understand these RT technologies' ability to spare the function of neighboring healthy tissues or organs like the salivary glands (SG).
Despite these research advances, a large majority of HNC patients who undergo RT display irreversible dry mouth symptoms (xerostomia) due to high radiation sensitivity of salivary gland (SG) secretory cells. This gland damage is thought to be triggered by an RT-induced loss of acinar cells and a potential impairment of the parasympathetic innervation and vascularization. Hence, the remaining integral SG stem/progenitor cells post-RT will define the true regenerative ability of the SG organ.
Cytoprotectant agents like amifostine have been recommended to prevent RT damage to SG cells. Amifostine is the only US Food and Drug Administration (FDA) approved drug for this prevention strategy. In Phase III clinical trials, amifostine was found to reduce xerostomia severity in subjects with grade two and above; however, more than 50% of subjects still presented acute xerostomia symptoms and oral mucosa inflammation. Moreover, amifostine has a very narrow therapeutic window. Therefore, frequent administration is required leading to severe side effects in more than half of the treated individuals. These side effects can lead to the discontinuation of amifostine treatment and RT delay in 25% of HNC patients. The high frequency of reported side effects and its high cost and low-quality evidence of efficacy from several clinical trials make amifostine a less promising pharmacological approach. Thus, novel pharmaceuticals are necessary to prevent SG damage and maintain the acinar epithelial and stem/progenitor cell populations in the SG organ.
In vitro and in vivo studies indicate green tea polyphenols (GTPs)/(-)-epigallocatechin-3-gallate (EGCG) as potential natural agents for xerostomia management, potentially delaying salivary dysfunction through molecular mechanisms. Researchers highlighted EGCG's role in suppressing autoantigens, influencing epithelial cell proliferation, and modulating antioxidant enzyme expression in salivary glands.
Peppermint essential oil is another herbal preparation with strong antibacterial and cooling effects. As a safe herbal preparation, peppermint essential oil has been found to be effective in alleviating the pain associated with aphthous stomatitis and managing dental plaque.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Asma A. Abou Bakr
- Email: Asmaa.Aboubakr@bue.edu.eg
Study Contact Backup
- Name: Fatma E.Sayed A Hassanein
- Phone Number: +201000093885
- Email: fatmahassanein@dent.asu.edu.eg
Study Locations
-
-
-
Cairo, Egypt, 11565
- Recruiting
- Ahmed Maher Teaching Hosipital
-
Contact:
- Fatma E.Sayed A Hassanein
- Phone Number: +201000093885
- Email: fatmahassanein@dent.asu.edu.eg
-
Cairo, Egypt, 11565
- Completed
- Ain Shams University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Both genders, aged above 20 years.
- All patients must have complaint of xerostomia.
- Objective dry mouth score from ( 2-5).
- Subjective dry mouth score from (1-4).
- Patients must be able to make reliable decision or communications.
Exclusion Criteria:
- - Smoking, Alcohol.
- Patient with history of any serious illness as malignancy.
- Patients with any autoimmune disease.
- Vulnerable groups such as pregnant females, prisoners, mentally and physically handicapped individuals.
- Known hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group:
patients in test group will topically apply 20 ml (green tea plus peppermint) (1:1) to the oral mucosa.
They will be instructed to keep green tea plus peppermint for at least 5 min duration and then to spit it out.
They will be advised to rinse 20 mL of green tea plus peppermint in the same manner before sleeping from fourth week of radiotherapy to three months after radiotherapy.
|
Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out [27]. The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben [28]. Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract. |
Placebo Comparator: Control group
Patients in the control arm will topically apply 20 mL of 0.9% of saline 15 min before and after radiotherapy.
They will be advised to rinse saline.
They will be instructed to keep saline for at least 5 min duration and then to spit it out.
They will be advised to rinse 20 mL of saline in the same manner before sleeping from fourth week of radiotherapy to three months after radiotherapy.
|
Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out [27]. The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben [28]. Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective symptoms of oral dryness
Time Frame: Three points: -"baseline which is at the fourth week of radiotherapy", -"the second point is at seventh week of the radiotherapy, while the end point is after three months of radiotherapy.
|
Using a questionnaire will be recorded according to the following: Q1. Does your mouth feel dry? Q2. Do you sip liquids to aid in swallowing dry food? Q3. Does your mouth feel dry when eating a meal? Q4. Does the amount of saliva in your mouth seem to be too little? Subject who answered affirmatively to at least one of the questions related to oral dryness will be considered as positive for subjective complaints of oral dryness. the score range frpm 1-4 according to the number of questions answered by yes |
Three points: -"baseline which is at the fourth week of radiotherapy", -"the second point is at seventh week of the radiotherapy, while the end point is after three months of radiotherapy.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective dry mouth score
Time Frame: Three points: -"baseline which is at the fourth week of radiotherapy", -"the second point is at seventh week of the radiotherapy, while the end point is after three months of radiotherapy.
|
• The patients will be examined for their signs of dry mouth including: (Osailan et al., 2011).
|
Three points: -"baseline which is at the fourth week of radiotherapy", -"the second point is at seventh week of the radiotherapy, while the end point is after three months of radiotherapy.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: dalia Ghalwash, Professor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- green tea and peppermint
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiation-induced Xerostomia
-
Qazvin University Of Medical SciencesImam Khomeini HospitalCompletedRadiation-Induced XerostomiaIran, Islamic Republic of
-
MeiraGTx, LLCActive, not recruitingRadiation-induced XerostomiaUnited States, Canada
-
Thomas KuhntVerband Deutscher DruckkammerzentrenTerminatedRadiation-induced XerostomiaGermany
-
Ain Shams UniversityRecruiting
-
MeiraGTx UK II LtdCompletedHead and Neck Cancer | Radiation-Induced Parotid Gland Hypofunction | Xerostomia Due to RadiotherapyUnited States, Canada
-
MeiraGTx, LLCNational Institute of Dental and Craniofacial Research (NIDCR)Active, not recruitingSquamous Cell Head and Neck Cancer | Radiation Induced Xerostomia | Salivary HypofunctionUnited States
-
Wake Forest University Health SciencesCompletedHead and Neck Cancer | Radiation Toxicity | Radiation-Induced Xerostomia | Oral Complications of Chemotherapy and Head/Neck RadiationUnited States
-
Dental Innovation Foundation Under Royal PatronageMahidol University; Ministry of Health, Thailand; Srinakharinwirot UniversityCompletedDry Mouth | Radiation-Induced Xerostomia | Cancer of Head NeckThailand
-
Dental Innovation Foundation Under Royal PatronageMahidol University; Ministry of Health, Thailand; Thammasat University; Srinakharinwirot...CompletedCancer | Cancer of Head and Neck | Dry Mouth | Radiation-induced XerostomiaThailand
-
National Institute of Dental and Craniofacial Research...CompletedRadiation Injuries | XerostomiaUnited States
Clinical Trials on mix of (green tea and peppermint)
-
The University of Hong KongCompleted
-
Taipei City HospitalNational Yang Ming UniversityCompletedType 2 Diabetes | HyperlipidemiaTaiwan
-
Chiang Mai UniversityCompletedHyperuricemia | GoutThailand
-
University of ArizonaUnited States Department of DefenseCompletedLung Cancer Prevention
-
University of MinnesotaNational Cancer Institute (NCI)Completed
-
Charite University, Berlin, GermanyCompleted
-
Liverpool John Moores UniversityUnilever R&DCompleted
-
University of AberdeenLipton Teas and InfusionsRecruitingThe Focus of the Study is Healthy VolunteersUnited Kingdom
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Martin-Luther-Universität Halle-WittenbergUniversity of Ulm; Deutsche Krebshilfe e.V., Bonn (Germany); KKS NetzwerkCompletedColorectal Serrated Adenomas | Colorectal Tubular Adenomas | Colorectal Villous Adenomas | Colorectal Tubulovillous AdenomasGermany